92 related articles for article (PubMed ID: 17094440)
1. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy.
Turner SD; Merz H; Yeung D; Alexander DR
Anticancer Res; 2006; 26(5A):3275-9. PubMed ID: 17094440
[TBL] [Abstract][Full Text] [Related]
2. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
Turner SD; Tooze R; Maclennan K; Alexander DR
Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
[TBL] [Abstract][Full Text] [Related]
3. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
Jäger R; Hahne J; Jacob A; Egert A; Schenkel J; Wernert N; Schorle H; Wellmann A
Anticancer Res; 2005; 25(5):3191-6. PubMed ID: 16101126
[TBL] [Abstract][Full Text] [Related]
4. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
5. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC
Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
[TBL] [Abstract][Full Text] [Related]
7. The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice.
Curtis DJ; Robb L; Strasser A; Begley CG
Oncogene; 1997 Dec; 15(24):2975-83. PubMed ID: 9416841
[TBL] [Abstract][Full Text] [Related]
8. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
Hsu FY; Zhao Y; Anderson WF; Johnston PB
Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
[TBL] [Abstract][Full Text] [Related]
10. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.
Chiarle R; Simmons WJ; Cai H; Dhall G; Zamo A; Raz R; Karras JG; Levy DE; Inghirami G
Nat Med; 2005 Jun; 11(6):623-9. PubMed ID: 15895073
[TBL] [Abstract][Full Text] [Related]
11. The anaplastic lymphoma kinase in the pathogenesis of cancer.
Chiarle R; Voena C; Ambrogio C; Piva R; Inghirami G
Nat Rev Cancer; 2008 Jan; 8(1):11-23. PubMed ID: 18097461
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.
Miething C; Grundler R; Fend F; Hoepfl J; Mugler C; von Schilling C; Morris SW; Peschel C; Duyster J
Oncogene; 2003 Jul; 22(30):4642-7. PubMed ID: 12879008
[TBL] [Abstract][Full Text] [Related]
13. ALK-positive diffuse large B-cell lymphoma.
Bubała H; Małdyk J; Włodarska I; Sońta-Jakimczyk D; Szczepański T
Pediatr Blood Cancer; 2006 May; 46(5):649-53. PubMed ID: 15852431
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic large cell lymphoma: redefining its morphologic spectrum and importance of recognition of the ALK-positive subset.
Chan JK
Adv Anat Pathol; 1998 Sep; 5(5):281-313. PubMed ID: 10021895
[No Abstract] [Full Text] [Related]
15. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2.
Larson RC; Fisch P; Larson TA; Lavenir I; Langford T; King G; Rabbitts TH
Oncogene; 1994 Dec; 9(12):3675-81. PubMed ID: 7970726
[TBL] [Abstract][Full Text] [Related]
16. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas.
Haralambieva E; Pulford KA; Lamant L; Pileri S; Roncador G; Gatter KC; Delsol G; Mason DY
Br J Haematol; 2000 Jun; 109(3):584-91. PubMed ID: 10886208
[TBL] [Abstract][Full Text] [Related]
18. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Medyouf H; Alcalde H; Berthier C; Guillemin MC; dos Santos NR; Janin A; Decaudin D; de Thé H; Ghysdael J
Nat Med; 2007 Jun; 13(6):736-41. PubMed ID: 17515895
[TBL] [Abstract][Full Text] [Related]
19. Genomic suppression of murine B29/Ig-beta promoter-driven transgenes.
Vettermann C; Lutz J; Selg M; Bösl M; Jäck HM
Eur J Immunol; 2006 Dec; 36(12):3324-33. PubMed ID: 17111355
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
Magro CM; Dyrsen ME
J Cutan Pathol; 2008 Nov; 35(11):1040-9. PubMed ID: 18681860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
